Item 8.01 Other Events.
On January 6, 2020, Minerva Neurosciences, Inc. (the "Company") issued a press
release providing details of the Company's completion of patient screening in a
Phase 3 clinical trial of roluperidone. A copy of the above referenced press
release is filed as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No. Description
99.1 Press Release of the Company dated January 6, 2020.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses